[1] Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 2012; 125: 1979−1987. doi: 10.1161/CIRCULATIONAHA.111.088591 [2] Sniderman AD, Lamarche B, Contois JH, et al. Discordance analysis and the Gordian knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 2014; 25: 461−467. doi: 10.1097/MOL.0000000000000127 [3] Pencina MJ, D’Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol 2015; 22: 1321−1327. doi: 10.1177/2047487315569411 [4] Wilkins JT, Li RC, Sniderman A, et al. Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. J Am Coll Cardiol 2016; 67: 193−201. doi: 10.1016/j.jacc.2015.10.055 [5] Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol 2021; 77: 1439−1450. doi: 10.1016/j.jacc.2021.01.027 [6] Liu Y, Jia SD, Yuan DS, et al. Apolipoprotein B/A-I ratio predicts lesion severity and clinical outcomes in diabetic patients with acute coronary syndrome. Circ J 2020; 84: 1132−1139. doi: 10.1253/circj.CJ-19-1097 [7] Balling M, Afzal S, Varbo A, et al. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J Am Coll Card iol 2020; 76: 2725−2735. doi: 10.1016/j.jacc.2020.09.610 [8] Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018; 392: 1311−1320. doi: 10.1016/S0140-6736(18)31652-0 [9] Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302−1309. doi: 10.1001/jama.2012.366 [10] Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759. doi: 10.1161/JAHA.113.000759 [11] Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol 2022; 7: 250−256. doi: 10.1001/jamacardio.2021.5083 [12] Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol 2019; 4: 1287−1295. doi: 10.1001/jamacardio.2019.3780 [13] Li T, Yuan D, Wang P, et al. Associations of lipid measures with total occlusion in patients with established coronary artery disease: a cross-sectional study. Lipids Health Dis 2022; 21: 118. doi: 10.1186/s12944-022-01733-8 [14] Michael Gibson C, Korjian S, Tricoci P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation 2016; 134: 1918−1930. doi: 10.1161/CIRCULATIONAHA.116.025687 [15] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111−188. doi: 10.1093/eurheartj/ehz455 [16] McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224−233. doi: 10.1016/S0140-6736(08)61076-4 [17] Walldius G, de Faire U, Alfredsson L, et al. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-experience from the Swedish AMORIS cohort: a cohort study. PLoS Med 2021; 18: e1003853. doi: 10.1371/journal.pmed.1003853 [18] Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction-is cholesterol a positive acute phase reactant?. Atherosclerosis 1999; 142: 389−393. doi: 10.1016/s0021-9150(98)00242-1 [19] Balci B. The modification of serum lipids after acute coronary syndrome and importance in clinical practice. Curr Ca rdiol Rev 2011; 7: 272−276. doi: 10.2174/157340311799960690 [20] Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20−28. doi: 10.1056/NEJMoa042378 [21] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119−1131. doi: 10.1056/NEJMoa1707914 [22] Lubrano V, Pingitore A, Traghella I, et al. Emerging biomarkers of oxidative stress in acute and stable coronary artery disease: levels and determinants. Antioxidants (Basel) 2019; 8: 115. doi: 10.3390/antiox8050115